View Post

Sermonix Reports FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene

In Clinical Trials by Barbara Jacoby

From: Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application, indicating that Sermonix may proceed directly to a Phase 2 clinical study in the personalized medicine arena involving its lead investigational drug, …